Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective

키워드

참고문헌 (89)

1. Zhou M, "Mortality, morbidity, and risk factors in China and its provinces, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 394, pp.1145~1158 (2019)
2. Sung H, "Global cancer statistics 2020 : GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185countries", CA Cancer J Clin, 71, pp.209~249 (2021)
3. Rumgay H, "Global burden of primary liver cancer in 2020 and predictions to 2040", J Hepatol, 77, pp.1598~1606 (2022)
4. de Martel C, "World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma", Hepatology, 62, pp.1190~1200 (2015)
5. Liang X, "Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination", Vaccine, 27, pp.6550~6557 (2009)
6. Zheng R, "Liver cancer incidence and mortality in China : Temporal trends and projections to 2030", Chin J Cancer Res, 30, pp.571~579 (2018)
7. Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 7, pp.6~ (2021)
8. Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE Study", Liver Int, 35, pp.2155~2166 (2015)
9. Zhou J, "Guidelines for the diagnosis and treatment of hepatocellular carcinoma(2019 edition)", Liver Cancer, 9, pp.682~720 (2020)
10. Zhou J, "Guidelines for diagnosis and treatment of primary liver cancer in China(2017 edition)", Liver Cancer, 7, pp.235~260 (2018)
11. Fan R, "aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis", J Hepatol, 73, pp.1368~1378 (2020)
12. Kokudo N, "Clinical practice guidelines for hepatocellular carcinoma : The Japan Society of Hepatology 2017(4th JSH-HCC guidelines)2019 update", Hepatol Res, 49, pp.1109~1113 (2019)
13. Zhou J, "Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma", J Clin Oncol, 29, pp.4781~4788 (2011)
14. Best J, "GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 18, pp.728~735 (2020)
15. Korean Liver Cancer Association (KLCA), "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clinical and Molecular Hepatology, 28(4), pp.583~705 (2022), 대한간학회
16. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
17. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
18. Llovet JM, "Novel advancements in the management of hepatocellular carcinoma in 2008", J Hepatol, 48(Suppl 1), pp.S20~S37 (2008)
19. Aubé C, "EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice", Liver Int, 37, pp.1515~1525 (2017)
20. Junghoan Park, "Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound", Clinical and Molecular Hepatology, 28(3), pp.362~379 (2022), 대한간학회[DOI]
21. Reig M, "BCLC strategy for prognosis prediction and treatment recommendation : The 2022 update", J Hepatol, 76, pp.681~693 (2022)
22. Kudo M, "Prognostic staging system for hepatocellular carcinoma(CLIP score) : its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score(JIS score)", J Gastroenterol, 38, pp.207~215 (2003)
23. Ueno S, "Prognostic performance of the new classification of primary liver cancer of Japan(4th edition)for patients with hepatocellular carcinoma : a validation analysis", Hepatol Res, 24, pp.395~403 (2002)
24. Yin L, "Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria : a RCT", J Hepatol, 61, pp.82~88 (2014)
25. Sun HC, "Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).", Hepatobiliary Surg Nutr, 11, pp.227~252 (2022)
26. Zhu XD, "Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and Anti-PD-1 antibody combinations", Liver Cancer, 10, pp.320~329 (2021)
27. Xie D, "Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world", Ann Transl Med, 9, pp.652~ (2021)
28. Liu BJ, "Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma", Immunotherapy, 13, pp.1395~1405 (2021)
29. Li PP, "Associating liver partition and portal vein ligation for staged hepatectomy versus sequential transarterial chemoembolization and portal vein embolization in staged hepatectomy for HBV-related hepatocellular carcinoma : a randomized comparative study", Hepatobiliary Surg Nutr, 11, pp.38~51 (2022)
30. Wang Z, "Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma : a single center study of 45 patients", Ann Surg, 271, pp.534~541 (2020)
31. Peng Y, "Transcatheter arterial embolization-salvaged ALPPS, a novel ALPPS procedure especially for patients with hepatocellular carcinoma and severe fibrosis", cirrhosis, 2022, pp.11, 504~514
32. Wang X, "Consensus guidelines for the use of fluorescence imaging in hepatobiliary surgery", Ann Surg, 274, pp.97~106 (2021)
33. Zhu P, "A prospective study using propensity score matching to compare long-term survival outcomes after robotic-assisted, laparoscopic or open liver resection for patients with BCLC stage 0-A hepatocellular carcinoma", Ann Surg (2022)[DOI]
34. Chen JF, "Laparoscopic vs. open repeat hepatectomy for recurrent liver tumors : a propensity score-matched study and meta-analysis", Front Oncol, 11, pp.646737~ (2021)
35. Song DJ, "Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma : a propensity score matching analysis", Surg Endosc (2022)[DOI]
36. Segev DL, "Steroid avoidance in liver transplantation : metaanalysis and meta-regression of randomized trials", Liver Transpl, 14, pp.512~525 (2008)
37. Liang W, "Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma : a meta-analysis", Liver Transpl, 18, pp.62~69 (2012)
38. Fan J, "Liver transplantation outcomes in 1, 078 hepatocellular carcinoma patients : a multi-center experience in Shanghai, China", J Cancer Res Clin Oncol, 135, pp.1403~1412 (2009)
39. Li J, "Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients", World J Gastroenterol, 15, pp.4170~4176 (2009)
40. Shi GM, "Graft programmed death ligand 1 expression as a marker for transplant rejection following anti-programmed death 1 immunotherapy for recurrent liver tumors", Liver Transpl, 27, pp.444~449 (2021)
41. Peng ZW, "Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma : a prospective randomized trial", J Clin Oncol, 31, pp.426~432 (2013)
42. Zhang R, "Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma", Diagn Interv Radiol, 24, pp.219~224 (2018)
43. Li HZ, "Chemoembolization plus microwave ablation vs chemoembolization alone in unresectable hepatocellular carcinoma beyond the milan criteria : a propensity scoring matching study", J Hepatocell Carcinoma, 8, pp.1311~1322 (2021)
44. Si ZM, "Combination therapies in the management of large(≥ 5 cm)hepatocellular carcinoma : microwave ablation immediately followed by transarterial chemoembolization", J Vasc Interv Radiol, 27, pp.1577~1583 (2016)
45. Wang X, "Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma : a propensity score matching analysis", Int J Hyperthermia, 38, pp.1519~1528 (2021)
46. Liang B, "Treatment response, survival, and safety of transarterial chemoembolization with CalliSpheres® microspheres versus conventional transarterial chemoembolization in hepatocellular carcinoma : a meta-analysis", Front Oncol, 11, pp.576232~ (2021)
47. Pung L, "The role of Cone-Beam CT in transcatheter arterial chemoembolization for hepatocellular carcinoma : a systematic review and meta-analysis", J Vasc Interv Radiol, 28, pp.334~341 (2017)
48. Wang Z, "Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection : a randomized controlled study", Clin Cancer Res, 24, pp.2074~2081 (2018)
49. Takuji Torimura, "Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects", Clinical and Molecular Hepatology, 27(2), pp.236~245 (2021), 대한간학회[DOI]
50. Kudo M, "Final results of TACTICS : a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma", Liver Cancer, 11, pp.354~367 (2022)
51. Li J, "Efficacy and safety of transcatheter arterial chemoembolization in combination with camrelizumab and targeted agents in intermediate-stage unresectable hepatocellular carcinoma : A single-arm, prospective, real-world study", J Clin Oncol, 40(16 suppl), pp.e16190~ (2022)
52. Yuan J, "Transarterial chemoembolization(TACE)combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus : a propensity score matching study", Biomed Res Int, 2019, pp.2141859~ (2019)
53. Peng Z, "Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma : a phase III, randomized clinical trial(LAUNCH)", J Clin Oncol, 41, pp.117~127 (2023)
54. Xia D, "Lenvatinib with or without concurrent drug-eluting beads transarterial chemoembolization in patients with unresectable, advanced hepatocellular carcinoma : a real-world, multicenter, retrospective study", Liver Cancer, 11, pp.368~382 (2022)
55. Ding X, "Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus : A prospective randomized study", Cancer, 127, pp.3782~3793 (2021)
56. Fu Z, "Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma(uHCC) : a retrospective controlled study", Hepatol Int, 15, pp.663~675 (2021)
57. Wu JY, "Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma : a multicenter retrospective study", J Hepatocell Carcinoma, 8, pp.1233~1240 (2021)
58. Hsu SJ, "Hepatic arterial infusion chemotherapy with modified FOLFOX as an alternative treatment option in advanced hepatocellular carcinoma patients with failed or unsuitability for transarterial chemoembolization", Acad Radiol, 28(Suppl 1), pp.S157~S166 (2021)
59. Lyu N, "Hepatic arterial infusion of oxaliplatin plus fluorouracil", leucovorin vs. sorafenib for advanced hepatocellular carcinoma, 2018, pp.69, 60~69
60. He M, "Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion : a randomized clinical trial", JAMA Oncol, 5, pp.953~960 (2019)
61. Lyu N, "Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma : a biomolecular exploratory, randomized, phase III trial(FOHAIC-1)", J Clin Oncol, 40, pp.468~480 (2022)
62. Li QJ, "Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma : a randomized phase III trial", J Clin Oncol, 40, pp.150~160 (2022)
63. Wang J, "Hepatic arterial infusion chemotherapy as a timing strategy for conversion surgery to treat hepatocellular carcinoma : a single-center realworld study", J Hepatocell Carcinoma, 9, pp.999~1010 (2022)
64. Li S, "Postoperative adjuvant hepatic arterial infusion chemotherapy(HAIC)with FOLFOX to improve outcomes of patients with hepatocellular carcinoma with microvascular invasion : A prospective multicenter, phase 3, randomized, controlled clinical trial", J Clin Oncol, 40(16 suppl), pp.4013~ (2022)
65. Wei X, "Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus : a randomized, open-label, multicenter controlled study", J Clin Oncol, 37, pp.2141~2151 (2019)
66. Zhang ZH, "Treatment of hepatocellular carcinoma with tumor thrombus with the use of iodine-125 seed strand implantation and transarterial chemoembolization : a propensity-score analysis", J Vasc Interv Radiol, 29, pp.1085~1093 (2018)
67. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
68. Ren Z, "Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study", Lancet Oncol, 22, pp.977~990 (2021)
69. Qin S, "Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma : a randomized, open-label, parallelcontrolled phase II-III trial", J Clin Oncol, 39, pp.3002~3011 (2021)
70. Qin S, "Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial", Ann Oncol, 33(Suppl 7), pp.S1401~S1402 (2022)
71. Qin S, "Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma", Ann Oncol, 33(Suppl 7), pp.S1402~S1403 (2022)
72. Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
73. Zhu AX, "Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.282~296 (2019)
74. Qin S, "Camrelizumab in patients with previously treated advanced hepatocellular carcinoma : a multicentre, open-label, parallel-group, randomised, phase 2 trial", Lancet Oncol, 21, pp.571~580 (2020)
75. Finn RS, "Primary results from the phase III LEAP-002 study : Lenvatinib plus pembrolizumab versus lenvatinib as first-line(1L)therapy for advanced hepatocellular carcinoma(aHCC)", Ann Oncol, 33(Suppl 7), pp.S1401~ (2022)
76. Zeng Z, "A retrospective study on the efficacy and safety of sorafenib or lenvatinib combined with sintilimab in patients with advanced hepatocellular carcinoma", J Clin Oncol, 39(15 suppl), pp.e16127~ (2021)
77. Chang X, "The best benefit population treated with lenvatinib plus anti-PD-1 for unresectable hepatocellular carcinoma", J Clin Oncol, 40(16suppl), pp.e16152~ (2022)
78. Yang X, "Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma : A large real-world study from two centers", J Clin Oncol, 40(16 suppl), pp.e16155~ (2022)
79. Sun H-C, "Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma : A realworld study", J Clin Oncol, 38(15 suppl), pp.e16610~ (2020)
80. Li Z, "Regorafenib combined with PD-1 monoclonal antibody in the second-line setting for hepatocellular carcinoma(HCC) : A retrospective, realworld study in China", J Clin Oncol, 40(16 suppl), pp.e16145~ (2022)
81. Yan T, "A retrospective study on the efficacy and safety of regorafenib or regorafenib combined with immune-checkpoint-inhibitors(ICIs)after firstline therapy in patients with advanced hepatocellular carcinoma", J Clin Oncol, 40(16 suppl), pp.e16115~ (2022)
82. Kelley RK, "Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312) : a multicentre, openlabel, randomised, phase 3 trial", Lancet Oncol, 23, pp.995~1008 (2022)
83. Cabibbo G, "COSMIC-312 : mounting immunotherapy enigmas for hepatocellular carcinoma", Lancet Oncol, 23, pp.e441~ (2022)
84. Abou-Alfa GK, "Phase 3 randomized, open-label, multicenter study of tremelimumab(T)and durvalumab(D)as first-line therapy in patients(pts)with unresectable hepatocellular carcinoma(uHCC) : HIMALAYA", J Clin Oncol, 40(4 suppl), pp.379~ (2022)
85. Yau T, "Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial", JAMA Oncol, 6, pp.e204564~ (2020)
86. El-Khoueiry AB, "Nivolumab(NIVO)plus ipilimumab(IPI)combination therapy in patients(Pts)with advanced hepatocellular carcinoma(aHCC) : Long-term results from CheckMate 040", J Clin Oncol, 39(3 suppl), pp.269~ (2021)
87. Xue F, "Efficacy and safety of second-line regorafenib after sorafenib or lenvatinib first line in patients with unresectable hepatocellular carcinoma : A realworld study", J Clin Oncol, 40(16 suppl), pp.e16125~ (2022)
88. Guyatt G, "GRADE guidelines : 1. Introduction-GRADE evidence profiles and summary of findings tables", J Clin Epidemiol, 64, pp.383~394 (2011)
89. Llovet JM, "Immunotherapies for hepatocellular carcinoma", Nat Rev Clin Oncol, 19, pp.151~172 (2022)

관련 논문AI추천